Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome

Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia. Leptin has been implicated as an antiapoptotic compound as well as a stimulant of the immune response. Leptin administration is capable of reversing the immune deficiency that occurs upon st...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 114(2005), 2 vom: 10. Feb., Seite 147-53
1. Verfasser: Goldberg, Anna Carla (VerfasserIn)
Weitere Verfasser: Eliaschewitz, Freddy Goldberg, Montor, Wagner Ricardo, Baracho, Gisele Vanessa, Errante, Paolo Ruggero, Callero, Mariana Alejandra, Cardoso, Maria Regina Alves, Braga, Patricia Emilia, Kalil, Jorge, Sogayar, Mari Cleide, Rizzo, Luiz Vicente
Format: Aufsatz
Sprache:English
Veröffentlicht: 2005
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Interleukin-2 Leptin Interleukin-4 207137-56-2
Beschreibung
Zusammenfassung:Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia. Leptin has been implicated as an antiapoptotic compound as well as a stimulant of the immune response. Leptin administration is capable of reversing the immune deficiency that occurs upon starvation. We investigated a possible role for leptin in CVID; a condition associated with lowered plasma leptin levels. Thirty-eight patients were studied. Addition of leptin to the tissue culture media of PBMC from CVID patients increased the proliferative response of lymphocytes to mitogens and decreased activation-induced apoptosis of these cells. IL-2 and specially IL-4 production also increased significantly upon addition of leptin to the PBMC cultures. Our results suggest that leptin may be involved in some of the cellular defects observed in CVID and indicate a novel therapeutic strategy to improve immune function in these patients
Beschreibung:Date Completed 08.03.2005
Date Revised 15.11.2006
published: Print
Citation Status MEDLINE
ISSN:1521-6616